Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, explains which patients with metastatic castration-resistant prostate cancer (mCRPC) are optimal for treatment with PARP inhibitors. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with mCRPC.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.